Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infection

Part of Human Metapneumovirus Infection

19 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Respiratory Syncytial Virus Infection

89 trials tracked for Respiratory Syncytial Virus Infection: 31 in phase 3 or 4 and 19 with published results. The most-cited published study has 421 citations.

89Trials tracked
31Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 4 1 Phase 3 30 Phase 2 29 Phase 1 16 Other / NA 13
  1. Phase 3 A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization Completed · 421 cited
  2. Phase 3 A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children Completed · 181 cited
  3. Phase 3 Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants Completed · 153 cited
  4. Phase 3 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) Completed · 73 cited
  5. Phase 3 Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above Completed · 50 cited
  6. Phase 3 Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age Completed · 43 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) Completed · 38 cited
  2. Phase 3 A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above Completed · 36 cited
  3. Phase 3 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age Completed · 24 cited
  4. Phase 3 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease Completed · 21 cited
  5. Phase 3 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above Completed · 18 cited
  6. Phase 3 A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above Completed · 14 cited
  7. Phase 3 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above Completed · 10 cited
  8. Phase 3 A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women. Completed · 5 cited
  9. Phase 3 A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above Completed · 4 cited
  10. Phase 3 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above Completed · 1 cited
  11. Phase 3 A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. Completed
  12. Phase 3 A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults Completed
  13. Phase 3 A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age Completed
  14. Phase 4 Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) Completed
  15. Phase 3 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Completed
  16. Phase 3 A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age Completed
  17. Phase 3 Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults Completed
  18. Phase 3 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above Completed
  19. Phase 3 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea Completed
  20. Phase 3 A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control Completed
  21. Phase 3 A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab Completed
  22. Phase 3 A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older Completed
  23. Phase 3 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Completed
  24. Phase 3 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Completed
  25. Phase 3 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children Completed
  26. Phase 2 Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season Completed
  27. Phase 2 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Completed
  28. Phase 2 A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants Completed
  29. Phase 2 A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus Completed
  30. Phase 2 Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers Completed
  31. Phase 2 Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants Completed
  32. Phase 2 Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Completed
  33. Phase 2 A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects Completed
  34. Phase 2 Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women Completed
  35. Phase 2 Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children Completed
  36. Phase 2 Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection Completed
  37. Phase 2 Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study Completed
  38. Phase 2 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. Completed
  39. Phase 2 Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) Completed
  40. Phase 2 Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Completed
  41. Phase 2 RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults Completed
  42. Phase 2 A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults Completed
  43. Phase 2 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age Completed
  44. Phase 2 Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Completed

Showing the 50 most-cited and recently-updated of 89 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
RSV vaccine safety findings reported one year after recommendation for adults 60 and older
Infectious Disease
RSV vaccine safety findings reported one year after recommendation for adults 60 and older Early safety monitoring of RSV vaccines for older adults shows no major concerns
A post-recommendation safety assessment in the United States examined outcomes in persons aged 60 years and older who received an RSV vaccin…
Safety checks a year after RSV vaccines were recommended for adults 60 and older found no major concerns during this initial period.
CDC Apr 4, 2026
ACIP recommends RSV vaccination for adults 60 years and older in the United States
Allergy & Immunology
ACIP recommends RSV vaccination for adults 60 years and older in the United States Should adults over 60 get the RSV vaccine? New recommendations say yes
The Advisory Committee on Immunization Practices (ACIP) issued a recommendation report for RSV vaccination in adults aged 60 years and older…
Adults 60 and older now have a clear official suggestion to get the RSV vaccine because the virus poses a significant health risk to this ag…
CDC Apr 4, 2026
ACIP Recommends Nirsevimab for Severe RSV Prevention in Infants and Young Children
Allergy & Immunology
ACIP Recommends Nirsevimab for Severe RSV Prevention in Infants and Young Children Should more infants get protection against severe RSV?
The Advisory Committee on Immunization Practices (ACIP) has issued a recommendation for using nirsevimab to prevent severe respiratory syncy…
A national health committee now recommends a preventive shot called nirsevimab to help infants avoid severe breathing problems caused by the…
CDC Apr 4, 2026
Field report describes nirsevimab rollout for RSV prevention in New York City infants
Pediatrics
Field report describes nirsevimab rollout for RSV prevention in New York City infants How many New York City infants got the new RSV shot this season?
A field report describes the rollout of nirsevimab for RSV prevention in infants born during the recommended administration period in New Yo…
New York City health officials released an early look at how many eligible infants received the new RSV shot this season.
CDC Apr 4, 2026
RSV Immunization Coverage Among US Infants Receiving Nirsevimab or Maternal Vaccination
Allergy & Immunology
RSV Immunization Coverage Among US Infants Receiving Nirsevimab or Maternal Vaccination How many infants are getting new RSV protection? A first look
An observational report describes RSV immunization coverage among US infants born from October 2023 to March 2024 who received nirsevimab mo…
For the first time, doctors have tools to protect youngest babies from RSV with new shots or pregnancy vaccines.
CDC Apr 3, 2026
CDC recommends clesrovimab for preventing severe RSV lower respiratory infections in infants
Allergy & Immunology
CDC recommends clesrovimab for preventing severe RSV lower respiratory infections in infants CDC recommends new antibody to protect infants from severe RSV
The CDC has issued a recommendation for the use of clesrovimab to prevent severe respiratory syncytial virus-associated lower respiratory tr…
The CDC now recommends a new antibody to help protect infants from severe respiratory syncytial virus infections.
CDC Apr 3, 2026
Palivizumab reduces medically attended RSV infections in preterm infants, shows similar efficacy to nirsevimab
Pediatrics Meta-analysis
Palivizumab reduces medically attended RSV infections in preterm infants, shows similar efficacy to nirsevimab Can an older RSV drug protect healthy preterm babies from doctor visits?
A meta-analysis of three randomized, placebo-controlled studies in 2,464 healthy infants born ≤35 weeks' gestational age found palivizumab r…
An older RSV shot cuts doctor visits for preterm babies by 70%, matching newer drugs, though safety details remain unclear.
Apr 2, 2026

Research across Human Metapneumovirus Infection

Related studies from across the Human Metapneumovirus Infection family.

Hospitalized children with HMPV infection had 28.0% severe CAP rates and higher risks of wheezing and co-infection
Emergency Medicine Cohort
Hospitalized children with HMPV infection had 28.0% severe CAP rates and higher risks of wheezing and co-infection Premature birth and wheezing raise severe HMPV pneumonia risk
This retrospective cohort study examined 878 hospitalized children with human metapneumovirus (HMPV)-positive community-acquired pneumonia (…
A study of 878 children finds premature birth and wheezing are strong predictors of severe HMPV pneumonia.
Frontiers May 1, 2026
Community cohort study examines symptomatic human metapneumovirus infection incidence
Infectious Disease
Community cohort study examines symptomatic human metapneumovirus infection incidence How common is this respiratory virus in the Pacific Northwest?
A community cohort study in Oregon and Washington assessed the average incidence of symptomatic human metapneumovirus infection.
A study in Oregon and Washington is tracking how often people get sick from human metapneumovirus, a virus that can cause serious breathing …
CDC Apr 5, 2026
Human metapneumovirus and respiratory syncytial virus co-circulation described in US
Infectious Disease
Human metapneumovirus and respiratory syncytial virus co-circulation described in US Two common respiratory viruses are circulating together in the US
A non-peer-reviewed report described co-circulation of human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) in the United Stat…
Two common respiratory viruses are circulating together in the US, creating a pattern that could lead to more people getting sick this seaso…
CDC Apr 5, 2026

Questions about Respiratory Syncytial Virus Infection

Can maternal vaccination protect infants from RSV alongside nirsevimab?

Yes, maternal RSV vaccination and the infant monoclonal antibody nirsevimab work together to protect babies, with nirsevimab providing the primary shield for the first RSV season.

Full answer →
Does nirsevimab prevent RSV in infants born in October 2023?

Yes, nirsevimab prevents RSV in infants born in October 2023, reducing hospitalizations by 70–90% during their first RSV season.

Full answer →
How does RSV disease severity compare to COVID-19 in older adults?

RSV and COVID-19 cause similar severe outcomes in older adults, including ICU admission and death, but RSV may pose higher risk of acute cardiac events.

Full answer →
Where is nirsevimab being rolled out for RSV prevention in infants?

Nirsevimab is being rolled out for infants in New York City and is recommended for high-risk groups including those living with HIV or exposed to HIV.

Full answer →
When do severe RSV outcomes peak in infants in low-income countries?

In low-income countries, severe RSV outcomes like hospitalization and death peak in infants between 2 and 5 months of age.

Full answer →
Can an assay accurately detect respiratory syncytial virus in clinical specimens from Georgia?

Yes, specific assays like whole-genome sequencing developed in Georgia have shown high accuracy for detecting respiratory syncytial virus in clinical specimens.

Full answer →
How does respiratory syncytial virus co-circulate with human metapneumovirus in the United States?

RSV and human metapneumovirus co-circulate in the US, especially during winter and spring, with overlapping seasonal patterns and similar disease spectra.

Full answer →
What is the current vaccination coverage for respiratory syncytial virus among US adults?

As of December 2023, RSV vaccination coverage among US nursing home residents was about 9.8%, with limited data for other adults.

Full answer →
See all 9 questions about Respiratory Syncytial Virus Infection →